MiR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Denoyelle, C ^a,b,c   Lambert, B ^a,b,c,d   Meryet Figuiere M ^a,b,c   Vigneron, N ^a,b,c   Brotin, E ^a,b,c   Lecerf, C ^a,b,c   Abeilard, E ^a,b,c   Giffard, F ^a,b,c   Louis, M H ^a,b,c   Gauduchon, P ^a,b,c   Juin, P ^e,f   Poulain, L ^a,b,c  

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c Comprehensive Cancer Center François Baclesse UNICANCER ^*  (France)

^d CNRS   (France)

^e UNIVERSITÉ DE NANTES   (France)

^f Centre Regional de Lutte contre le Cancer   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; BIM PROTEIN; CETUXIMAB; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MICRORNA; MICRORNA 491 5P; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BCL2L1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MEMBRANE PROTEIN; MIRN491 MICRORNA, HUMAN; ONCOPROTEIN; PROTEIN BCL X;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CARCINOMA; GENETICS; METABOLISM; OVARY TUMOR; PATHOPHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; MEMBRANE PROTEINS; MICRORNAS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925535237     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.389     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advancedstage epithelial ovarian cancer. Nat Rev Clin Oncol 2013; 10: 211-224.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
4. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15:49-63.
5. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-132.
6. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 2013; 13: 455-465.
7. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'Diaye M et al. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatinresistant ovarian carcinoma cells. Mol Cancer Ther 2009; 8: 3162-3170.
8. Brotin E, Meryet-Figuiere M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J et al. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 2010; 126: 885-895.
9. Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M et al. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis 2013; 18: 492-508.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
11. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
12. Lages E, Ipas H, Guttin A, Nesr H, Berger F, Issartel JP. MicroRNAs: molecular features and role in cancer. Front Biosci 2012; 17: 2508-2540.
13. Di Leva G, Croce CM. The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol 2013; 3: 1-10.
14. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 2010;42: 1262-1272.
15. Van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010; 42: 1282-1290.
16. Dweep H, Sticht C, Gretz N. In-silico algorithms for the screening of possible microRNA binding sites and their interactions. Curr Genomics 2013; 14: 127-136.
17. Harada H, Grant S. Targeting the regulatory machinery of BIM for cancer therapy. Crit Rev Eukaryot Gene Expr 2012; 22: 117-129.
18. Faber AC, Ebi H, Costa C, Engelman JA. Apoptosis in targeted therapy responses: the role of BIM. Adv Pharmacol 2012; 65: 519-542.
19. Dobbin ZC, Landen CN. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013; 14: 8213-8227.
20. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVPBEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011; 17: 2373-2384.
21. Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using PI3K/Mtor dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Cancer Lett 2014; 348: 38-49.
22. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010; 127: 1072-1080.
23. Guo R, Wang Y, Shi WY, Liu B, Hou SQ, Liu L. MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules 2012; 17: 14733-14747.
24. Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol 2014; 8: 93-104.
25. Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 2011; 1411: 108-115.
26. Rutnam ZJ, Yang BB. The non-coding 3' UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci 2012; 125: 2075-2085.
27. Huang WC, Chan SH, Jang TH, Chang JW, Ko YC, Yen TC et al. miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. Cancer Res 2014; 74: 751-764.
28. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105: 7004-7009.
29. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA 2013; 110: 9845-9850.
30. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-865.
31. Li X, Liu Y, Granberg KJ, Wang Q, Moore LM, Ji P et al. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene 2014; e-pub ahead of print 21 April 2014; doi:10.1038/onc.2014.98.
32. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007; 4: 1669-1679.
33. Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007; 67: 11867-11875.
34. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008; 118: 3651-369.
35. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012; 21: 547-562.
36. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
37. Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal 2013; 6: ra20.
38. Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P et al. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 2012; 4: 447-469.
39. Ichimura A, Ruike Y, Terasawa K, Tsujimoto G. miRNAs and regulation of cell signaling. FEBS J 2011; 278: 1610-1618.
40. Roshan Moniri M, Young A, Reinheimer K, Rayat J, Dai LJ, Warnock GL. Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology 2014; e-pub ahead of print 19 January 2014.
41. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622.